Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy
Diabetes · 2025
DOI: 10.2337/db24-0822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Qin Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shangha…. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Vascular Endothelial Growth Factor A, Retina, Bevacizumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NEI NIH HHS, Janssen Pharmaceutical research grant.
Abstract (Originalsprache)
Anti-vascular endothelial growth factor (anti-VEGF) therapies are effective treatment of severe diabetic retinopathy (DR) and macular edema, but a significant subset of people showed inadequate response to anti-VEGF intervention. Since elevation or overexpressing retinol binding protein 3 (RBP3) decreased risks for retinal pathologies and progression to severe DR, we compared the therapeutic profile of RBP3 and anti-VEGF to normalize retinal dysfunctions induced by diabetes. Intravitreous injection of recombinant human RBP3 (rhRBP3) and anti-VEGF antibodies (bevacizumab) inhibited retinal vascular permeability in Lewis rats induced by VEGF-A or after 2 months of diabetes induced by streptozotocin, in parallel with reductions of retinal VEGF and VEGFR2 expressions and tyrosine phosphorylation of VEGFR. Only rhRBP3 ameliorated diabetes induced reduction of neural retinal function, measured by electroretinogram. Further, rhRBP3 reduced retinal expressions of inflammatory cytokines (TNFα and IL6) in retinal pigmented epithelial and Müller cells exposed to hyperglycemia. Metabolic studies, using Seahorse, showed only rhRBP3 normalized retinal glycolytic rates in diabetic rats. Thus, both intravitreous anti-VEGF antibodies and RBP3 injections normalized retinal vascular dysfunctions caused by diabetes. Only RBP3 targeted both neural and vascular retina to reduce glycolytic rates, reversed neural-retinal dysfunctions, and reduced inflammatory cytokines induced by diabetes, to delay early changes of DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Harvard Medical School, Boston, MA.
- Department of Ophthalmology, Harvard Medical School, Boston, MA.
- Department of Medicine, Harvard Medical School, Boston, MA.
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Ward Fickweiler, Maha Sharawy, George L King
Förderung
- NIDDK NIH HHS
- NEI NIH HHS
- Janssen Pharmaceutical research grant
Zitieren
APA
Li, Q., Onizuka, S., Park, K., Ma, M., Fickweiler, W., Park, H., Li, Q., Simao, F., Boisclair, J., Sharawy, M., Wu, I. H., Yu, M. G., Aiello, L. P., Sun, J. K., & King, G. L. (2025). Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy. Diabetes. https://doi.org/10.2337/db24-0822
Vancouver
Li Q, Onizuka S, Park K, Ma M, Fickweiler W, Park H, et al. Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy. Diabetes. 2025. doi:10.2337/db24-0822
BibTeX
@article{Li2025,
author = {Li, Qin and Onizuka, Satoru and Park, Kyoungmin and Ma, Mingming and Fickweiler, Ward and Park, Hyunseok and Li, Qian and Simao, Fabricio and Boisclair, Jared and Sharawy, Maha and Wu, I-Hsien and Yu, Marc Gregory and Aiello, Lloyd P and Sun, Jennifer K and King, George L},
title = {Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy},
journal = {Diabetes},
year = {2025},
doi = {10.2337/db24-0822}
}
EUVIMED